
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc is positioned favorably due to its promising clinical pipeline, particularly with seralutinib, which has shown significant efficacy in reducing NT-proBNP and improving heart function in patients with pulmonary arterial hypertension (PAH). The anticipated initiation of a Phase 3 trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the second half of 2025 highlights the potential for expanding its market footprint amid substantial unmet medical needs. With key data readouts and multiple catalysts expected in the near term, Gossamer Bio's strategic direction underscores a positive outlook for the company.
Bears say
Gossamer Bio Inc. faces significant challenges due to the competitive landscape in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), particularly as studies indicate poor prognosis among afflicted patients. The potential inability to gain necessary product labels and effectively market its pipeline treatments could hinder the company's market traction and financial performance. Additionally, the possibility of shareholder dilution, compounded by an already limited therapeutic landscape, raises concerns about the company's ability to meet or exceed market expectations, further contributing to a negative financial outlook.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares